Emergent BioSolutions Inc. (EBS:NYSE) closed at $5.79 on November 13, 2026, down 1.70% on the day. The stock trades 58.8% below its 52-week high of $14.06 and 32.8% above its 52-week low of $4.36. Over the past year, it lost 42.7%. Emergent BioSolutions Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, EBS closed higher on 115 days (46%). Its best day was October 5, 2026 (+14.38%) and its worst was August 6, 2026 (-29.58%). The stock moved 10% or more in a single session 7 times. It opened at least 5% above the previous day's high 1 time.
Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT (Botulism Antitoxin Heptavalent) for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride. Its investigational stage product candidates include NuThrax, a next generation anthrax vaccine; UV-4B for dengue and influenza infections; GC-072 for Burkholderia pseudomallei; FLU-IG (NP025), a human polyclonal antibody therapeutic being developed to treat seasonal influenza; ZIKA-IG (NP024), a human polyclonal antibody therapeutic being...
Find more stocks like EBS with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.